Bispecific T cells expressing both HER2 and IL13Rα2 CARs exhibited greater activation and antitumor activity in in vitro and ex vivo experiments and in an orthotopic xenograft model of human GBM compared to HER2 CAR-T cells alone, IL13Rα2 CAR-T cells alone or pooled HER2 and IL13Rα2 CAR-T cells. This evidence concerns the gene ERBB2 and glioblastoma.